The global clinical trial equipment & ancillary solutions market size is expected to reach USD 5.10 billion by 2030, expanding at a CAGR of 8.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growing pharmaceutical and medical sectors, globalization of clinical trials, and rising R&D expenditure are the factors driving the market. However, the COVID-19 pandemic has affected the global market, which resulted in slowing down the supply chain of equipment & ancillary supplies. The COVID-19 pandemic has caused major changes in the clinical trial environment. Hundreds of experiments were in progress before the pandemic was halted due to COVID-19 globally. However, the growing demand for new and better treatment options has improved the number of clinical trial in the post-pandemic.
The clinical trial procedure has evolved considerably in recent years. Complex clinical studies are creating new problems throughout the healthcare supply chain. Modern studies frequently involve huge numbers of patients and patient subgroups, as well as numerous nations and research sites. As a result, the number of challenges that supply chain managers confront while working with clinical trial equipment & ancillaries has increased. Renting medical equipment relieves the burden of storage, retrieval, and disposal. Another important decision-making reason is that renting equipment reduces significant upfront expenses and large investments required to furnish licensed clinical trial locations.
The pandemic has created a need for effective therapies and interventions. COVID-19 has changed the way clinical trials are conducted, encouraging the digitization of healthcare and the adoption of cutting-edge technologies and techniques. Such adoptions are likely to propel market growth. Moreover, the high R&D spending by the pharmaceutical company for developing innovative therapies for COVID-19 has further contributed to the market growth.
Request a free sample copy or view report summary: Clinical Trial Equipment & Ancillary Solutions Market Report
The supply/logistics product segment dominated the market with a revenue share of more than 38.95% in 2023 due to the high number of clinical trials globally, which resulted in increased demand for efficient logistics services
The phase III segment dominated the market in 2023 and is expected to maintain its dominance through 2030. Phase III studies are the most effective approach to discovering a new treatment standard
North America led the global market in 2022 and is expected to remain dominant even during the forecast years due to a rise in the number of CRO and pharmaceutical & medical companies in the region
Asia Pacific is anticipated to witness fastest growth in the clinical trial equipment and ancillary solutions market during the forecast period as it is becoming an increasingly significant site for clinical trial investigations
Grand View Research has segmented the global clinical trial equipment & ancillary solutions market based on Product, phase, and region:
Clinical Trial Equipment & Ancillary Solutions Product Outlook (Revenue, USD Million, 2018 - 2030)
Sourcing
Procurement
Equipment
Ancillaries
Rental
Equipment
Ancillaries
Supply/Logistics
Transportation
Packaging
Others
Service
Calibrations
Equipment Servicing
Others
Others
Clinical Trial Equipment & Ancillary Solutions Phase Outlook (Revenue, USD Million, 2018 - 2030)
Phase I
Phase II
Phase III
Phase IV
Clinical Trial Equipment & Ancillary Solutions Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
China
India
Japan
Australia
Thailand
South Korea
Latin America
Brazil
Mexico
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players of Clinical Trial Equipment & Ancillary Solutions Market
Ancillare, LP
Imperial CRS, Inc.
Woodley Equipment Company Ltd.
Thermo Fisher Scientific, Inc.
Parexel International (MA) Corporation
Emsere (formerly MediCapital Rent)
Quipment SAS
IRM
Marken
Myonex
Yourway
"The quality of research they have done for us has been excellent..."